补中益气汤合穴位揿针联合化疗治疗晚期肺腺癌临床疗效观察

中华养生保健 ›› 2023, Vol. 41 ›› Issue (3): 4-8.

补中益气汤合穴位揿针联合化疗治疗晚期肺腺癌临床疗效观察

丁振洋¹, 刘芳¹, 朱飞¹, 陈风^1,*, 孙子凯², 任占良³, 瞿晨雪¹

1.南京医科大学康达学院附属盱眙人民医院呼吸与危重症医学科,江苏淮安,211700;
2.南京中医药大学附属医院呼吸与危重症医学科,江苏南京,210029;
3.陕西中医药大学附属医院胸心外科,陕西咸阳,712000

出版日期:2023-02-01 发布日期:2023-02-06
通讯作者: ^* 陈风,E-mail：804331386@qq.com。
作者简介:丁振洋（1993—）,男,汉族,籍贯：江苏省淮安市,硕士研究生,住院医师,研究方向：呼吸系统疾病临床研究。
基金资助:
江苏省“十二五”中医药重点学科建设项目（js1302）; 江苏省第三批名老中医药专家传承工作室建设项目[编号：苏中医科教（2019）10号]

Clinical Observation of Buzhong Yiqi Decoction Plus Acupoint Intradermal Needling Combined with Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma

DING Zhen-yang¹, U Fang¹, ZHU Fei¹, CHEN Feng^1,*, SUN Zi-kai², REN Zhan-liang³, QU Chen-xue¹

1. Department of Respiratory and Critical Care Medicine, Xuyi People's Hospital, Kangda College, Nanjing Medical University, Huai'an Jiangsu, 211700, China;
2. Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing Jiangsu, 210029, China;
3. Department of Cardiothoracic Surgery, Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Xianyang Shaanxi, 712000, China

Online:2023-02-01 Published:2023-02-06

摘要/Abstract

摘要： 目的探讨补中益气汤加减方合穴位揿针联合化疗治疗晚期肺腺癌的临床疗效。方法选取2020年1月—2021年12月盱眙人民医院收治的晚期不可手术切除、驱动基因阴性的肺腺癌患者60例,按照随机数表法分为对照组和观察组,每组30例。对照组应用西医规范化疗+免疫治疗,观察组在对照组治疗基础上联合补中益气汤加减方+穴位揿针治疗,观察两组患者的临床症状改善情况、生存质量评分、肿瘤标志物水平和不良反应。结果观察组患者的胸闷、乏力、纳差症状改善率显著高于对照组（P<0.05）;两组治疗后的生存质量KPS评分较治疗前均有所改善（P<0.05）,且观察组治疗后KPS评分改善情况高于对照组（P<0.05）;观察组治疗后血清肿瘤标志物CEA和CYFRA21-1数值下降幅度较对照组大（P<0.05）;对照组患者头晕、恶心呕吐、骨髓抑制的发生率显著高于观察组（P<0.05）。结论在治疗晚期不可手术切除、驱动基因检测阴性的肺腺癌患者过程中,在常规化疗+免疫治疗基础上,联合补中益气汤加减、穴位揿针治疗,可以有效减轻患者的临床症状,提高生存质量,并降低化疗等引起的不良反应,具有应用价值。

关键词: 晚期肺腺癌, 补中益气汤, 穴位揿针, 疗效, 不良反应

Abstract: Objective To explore the clinical efficacy of Buzhong Yiqi Decoction plus acupoint intradermal needling combined with chemotherapy for advanced and driver gene test negative lung adenocarcinoma. Methods A total of 60 patients with advanced unresectable lung adenocarcinoma who were treated in Xu Yi People's Hospital from January 2020 to December 2021. They were randomly divided into two groups, the observation group and the control group. The control group was treated with standard western medicine chemotherapy and immunotherapy, and the treatment group was treated with the control group Combined with Buzhong Yiqi Decoction Modified Recipe and acupoint intradermal needling, improvement of clinical symptoms, quality of life score, tumor marker level and adverse reactions of the two groups were observed. Results The improvement rates of chest tightness, fatigue and anorexia in the treatment group were significantly higher than those in the control group (P<0.05); the KPS scores of the quality of life after treatment were improved compared with those before treatment (P<0.05), but the KPS of the treatment group after treatment was better than the control group (P<0.05); after treatment, the serum CEA and CYFRA21-1 values in the treament group decreased more than those in the control group (P<0.05); the incidence of dizziness, nausea, vomiting and bone marrow suppression in the control group was significantly higher than that in the treament group (P<0.05). Conclusion In the treatment of advanced unresectable and driver gene test negative lung adenocarcinoma patients, on the basis of conventional chemotherapy and immunotherapy, combined with Buzhong Yiqi Decoction plus acupoint intradermal needling can effectively relieve the clinical symptoms of patients, improve the quality of life and reduce the Toxic effects caused by chemotherapy, so have promotion value.

Key words: advanced lung adenocarcinoma, buzhong yiqi decoction, acupoint intradermal needling, clinical efficacy, toxic reaction

中图分类号:

R734

丁振洋, 刘芳, 朱飞, 陈风, 孙子凯, 任占良, 瞿晨雪. 补中益气汤合穴位揿针联合化疗治疗晚期肺腺癌临床疗效观察[J]. 中华养生保健, 2023, 41(3): 4-8.

DING Zhen-yang, U Fang, ZHU Fei, CHEN Feng, SUN Zi-kai, REN Zhan-liang, QU Chen-xue. Clinical Observation of Buzhong Yiqi Decoction Plus Acupoint Intradermal Needling Combined with Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma[J]. ZHONGHUA YANGSHENG BAOJIAN, 2023, 41(3): 4-8.

参考文献

[1] Sung H, Ferlay J, Siegel R L, et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries[J]. CA Cancer J Clin,2021,71(3):209-249.
[2] Allemani C, Matsuda T, Di Carlo V, et al.Global surveillance of trends in cancer survival 2000-14 (CONCORD-3):analysis of individual records for 37513025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J]. Lancet,2018,391(10125):1023-1075.
[3] Lu S, Cheng Y, Zhou C C, et al.Meta-Analysis of First-Line Pemetrexed Plus Platinum Treatment in Compared to Other Platinum-Based Doublet Regimens in Elderly East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer[J]. Clin Lung Cancer,2016,17(5):103-112.
[4] 徐杉智,余功,谢斌.肺癌的病机分析及方剂应用探索[J].辽宁中医杂志,2018,45(2):270-272.
[5] 李东垣. 内外伤辨惑论[M].北京:中国医药科技出版社,2011:15-16.
[6] 中华医学会,中华医学会肿瘤学分会,中华医学会杂志社.中华医学会肺癌临床诊疗指南(2018版)[J].中华肿瘤杂志,2018,40(12):935-964.
[7] 余小萍,方祝元.中医内科学(第3版)[M].上海:上海科学技术出版社,2018:353-364.
[8] 国家中医药管理局.中医病证诊断疗效标准[M].南京:南京大学出版社,1994:2,5,7.
[9] 张培形,于明薇,杨宗艳,等.中晚期非小细胞肺癌中西医疗效评价方法比较研究[J].中国中西医结合杂志,2010,30(7):702-705.
[10] 李燕星,张光霁,阮善明,等.非小细胞肺癌不同时期的中医治法[J].中华中医药杂志,2018,33(8):3532-3534.
[11] Gadgeel S, Rodríguez-Abreu D, Speranza G, et al.Updated Analysis From KEYNOTE-189:Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer[J]. J Clin Oncol,2020,38(14):1505-1517.
[12] Nasser N J, Gorenberg M, Agbarya A.First line Immunotherapy for Non-Small Cell Lung Cancer[J]. Pharmaceuticals (Basel),2020,13(11):373.
[13] 王学谦,侯炜,郑佳彬,等.中医综合治疗方案维持治疗晚期非小细胞肺癌的多中心、大样本、前瞻性队列研究[J].中医杂志,2020, 61(8):690-694.
[14] 张博,李雁.肺癌可从胸痹论治[J].辽宁中医杂志,2020,47(12):54-56.
[15] 谢卓恩. 补中益气汤加味治疗脾胃虚弱型慢性萎缩性胃炎的临床疗效观察[D].南宁:广西中医药大学,2018:31-34.
[16] 徐国品. 补中益气汤改善肺脾气虚型晚期非小细胞肺癌患者生活质量的临床研究[D].合肥:安徽中医药大学,2019:25-27.
[17] Park B, You S, Cho W C S, et al. A systematic review of herbal medicines for the treatment of cancer cachexia in animal models[J]. J Zhejiang Univ Sci B,2019,20(1):9-22.
[18] 唐倩,廖大忠,李修元.皮内针联合西药治疗肿瘤化疗后恶心呕吐的临床研究[J].中医药学报,2018,46(5):54-57.
[19] 赵兰风,马洪举,曾科学,等.针刺改善肿瘤放化疗术后白细胞减少症的临床观察[J].辽宁中医杂志,2019,46(7):1521-1522.